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Abstract Heart failure (HF) is a major cardiovascular com-
plication of diabetes mellitus (DM). The greatest risk factor
for HF is age, and data indicate that 6 to 10 % of individuals
over the age of 65 years suffer from HF. Patients with DM
have a 2.5-fold increased risk for developing HF than individ-
uals without DM. The 25 to 40 % of patients with HF who
have DM have worse outcome (death from cardiovascular
disease or hospitalization for worsening HF) than patients
without DM. Hyperglycemia is a risk factor for the develop-
ment of HF with an increase in incidence of HF rising from
10 % at hemoglobin A1c (HbA1c) 8.0 to 9.0 % to 71 % at a
HbA1c > 10 %. Patients with DM and HF are equally distrib-
uted between those with low ejection fractions and those with
normal ejection fractions. The HF treatment regimens for pa-
tients with HF and DM (blockade of angiotensin II synthesis
or action, cardioselectiveβ-adrenergic blockade, mineralocor-
ticoid receptor blockade, and diuretics) are the same as for HF
patients without DM, though the benefit on clinical outcomes
is not as great. The new angiotensin-neprilysin inhibitors ap-
pear to provide increase outcome benefits in both HF patients
with or without DM. Glycemic control impacts the clinical
outcomes in patients with HF and DM in a U-shaped relation-
ship with poorer survival at low and high mean HbA1c levels.
The optimal chronic glycemic control occurs at an HbA1c of
7.5 to 8.0 % for patients with DMwho have symptoms of HF.
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Introduction
Heart failure (HF), a major cardiovascular (CV) complication
of diabetes mellitus (DM), has finally emerged as a significant
and increasing clinical and public health problem. Several
changes in society have coalesced to cause this merger of
HF with DM. HF incidence increases with age and is present
in 6 to 10 % of individuals 65 years or older [1–3]. This is the
most rapidly growing segment of the population in western
societies. The lifetime risk of HF at age 55 years is 33 % for
men and 28 % for women. The 5-year mortality for persons
with HF is approximately 50 %. The prevalence of DMwhich
now is about 415 million persons worldwide is projected to
increase by an additional 50 % to 642 million by 2040 [4].
It should not be surprising that the population with both
DM and HF is currently between 0.3 and 0.5% of the total and
is growing rapidly. The prevalence of previously diagnosed
type 2 diabetes (T2DM) in an HF population is 25 to 35 %,
and in more severe hospitalized HF patients, it may be as high
as 40 % [5••, 6, 7].
The incidence of HF in patients with clinically diagnosed
DM is approximately 2.5 times that in patients without DM [8,
9]. The development of clinical HF in patients with DM is
associated with a significantly poorer outcome as measured
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by CV death or admission to the hospital with worsening HF
than comparable non-diabetic subjects [5••, 10–12].
This manuscript focuses on the integration of HF and gly-
cemic management in the increasing population of T2DM and
clinical HF to provide preventative and treatment strategies to
decrease the prevalence and improve the clinical outcomes for
these patients.
Epidemiology
One of the early reports of the high prevalence of HF in pa-
tients with DM (2.5-fold in men and 5-fold in women) com-
pared to non-diabetic individuals came from the Framingham
cohort in 1974 [8]. One of the problems in appreciating the
importance of HF in patients with DM is the heterogeneity and
complexity of developing a mechanistic definition of HF. HF
is defined by the American College of Cardiology Foundation
(ACCF)/American Heart Association (AHA) guidelines [13]
as Ba complex clinical syndrome that can result from any
structural or functional cardiac disorder that impairs the ability
of the ventricle to fill with or eject blood. The cardinal man-
ifestations of HF are dyspnea and fatigue, which may limit
exercise tolerance and fluid retention, which may lead to pul-
monary congestion and peripheral edema.^HF is classified by
the left ventricular ejection fraction (LVEF). The older classi-
fication was vague in that HF with preserved LVEF was de-
fined as ≥50 % and with reduced LVEF as ≤40 %, with that
between 40 and 50 % arbitrarily assigned one or the other
depending on the study design. The more recent classification
proposed by the European Heart Association [1] defines
LVEF < 40 % as HFrEF (reduced), >40 to 49 % as HFmEF
(intermediate), and ≥50 % as HFpEF (preserved). In addition,
the diagnosis of HFmEF and HFpEF requires an elevated
level of natriuretic peptide and either one or both structural
heart disease with left ventricular hypertrophy (LVH) or left
atrial enlargement (LAE) or evidence of diastolic dysfunction.
The severity of HF is usually defined by the NY Heart
Association (NYHA) Classification published in 1964 [14]
and/or the ACC/AHA 2009 Guidelines for the Diagnosis
and Management of Heart Failure in Adults [13], both of
which are provided in Table 1.
Nichols et al. published a retrospective analysis in 2004 of
8231 patients with T2DM and 8845 non-diabetic patients of
similar age and sex who did not have HF at entry in 1997 and
were followed for up to 72 months for the development of HF
[9]. The patients with T2DM developed 30.9 cases of HF/
1000 person-years compared to 12.4 cases/1000 person-
years in the non-diabetic individuals (P < 0.001). The odds
ratio (OR) for HF in all the patients with T2DM as compared
to those without DM was 2.5. However, the OR was highly
dependent on age: 11.0 at <45 years, 8.6 at 45 to 54 years,
4.4 at 55 to 64 years decreasing to 1.8 at 75 to 84 years. Risk
factors for the development of HF in the diabetic population
were previous history of ischemic heart disease, poorer glyce-
mic control (hazard ratio (HR) = 1.32 per percentage point of
hemoglobin A1c (HbA1c)), and greater body mass index
(BMI) (HR = 1.12 per 2.5 units of BMI). Many subsequent
studies have confirmed the marked increase in HF in patients
with DM compared to non-diabetic individuals [5••, 10, 15,
16]. Data from the Reduction of Atherothrombosis for
Continued Health from the (REACH) registry published in
2015 reported results of a 4-year follow-up of 45,227 patients
with high-risk atherothrombosis disease of whom 43.6 % had
DM at baseline [5••]. In addition to the increase in prevalence
of HF observed in the diabetic population, there was also a
marked increase in all CVoutcomes including death and hos-
pitalization for HF over the 4-year follow-up.
The Organized Program to Initiate Lifesaving Treatment in
Hospitalized Patients with Heart Failure (OPTIMIZE-HF)
program was a patient registry and performance improvement
program for patients hospitalized with HF. The study regis-
tered 48,612 patients from 259 hospitals. Forty-two percent of
the patients had DM [15].
The incidence of HF in patients with DM increases with
poor glycemic control. Data from Kaiser Permanente Medical
Care of Northern California reported an 8 % increase in HF
risk for every 1% increase in HbA1c in a population of 48,858
patients with DM followed for a median of 2.2 years [17].
Data from a Swedish National Diabetes Registry of 83,021
patients with T2DM examined the relationship between
Table 1 Classification of heart failure
New York Heart Association Classification of Heart Failure [14]
Class 1 No limitation of physical activity. Ordinary
physical activity does not cause undue
fatigue, palpitations, dyspnea, or angina pain
Class 2 Slight limitation of physical activity. Patients
are comfortable at rest. Ordinary physical
activity results in fatigue, palpitation, dyspnea,
or angina pain
Class 3 Marked limitation of physical activity. Patients
are comfortable at rest. Less than ordinary
activity causes fatigue, palpitation, dyspnea,
or angina pain
Class 4 Inability to carry on any physical activity without
discomfort. Symptoms of heart failure or the
angina syndrome may be present even at rest.
Any physical activity increases discomfort.
American College of Cardiology/American Heart Association
Classification of Heart Failure [13]
Stage A High risk for HF but without structural heart
disease or symptoms of HF
Stage B Structural heart disease but without signs of
symptoms of HF
Stage C Structural heart disease with prior or current
symptoms of HF
Stage D Refractory HF requiring specialized interventions
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glycemic control and hospitalization for HF in patients in the
registry 1998 to 2003 who were followed up for a mean of
7.2 years [18]. A total of 10,969 (13.2 %) were hospital-
ized with a primary or secondary diagnosis of HF. Male
sex, older age, and longer duration of DM increased the
incidence of HF hospitalization (P < 0.001). HbA1c was
a major risk factor for the development of HF. No in-
creased risk of HF hospitalization was observed with
HbA1c < 7 %. A slight increase in risk was observed
with HbA1c 7.0 to <8.0 %. The risk for HF hospitali-
zation increased progressively from HbA1c 8.0 to <9.0,
9.0 to <10.0, and >10.0 % (HRs = 1.10, 1.27, and 1.71,
respectively, P < 0.001).
BMI has been identified as a risk factor for the develop-
ment of HF in persons with T2DM in several clinical studies
[19•, 20]. The Swedish National Diabetes Registry study cited
above also determined the effect of BMI on hospitalizations
for HF over the same 7.2-year follow-up [19•]. Cox regression
analysis of the effect of BMI on HF development adjusting for
age, sex, HbA1c, blood pressure, DM duration, smoking,
microalbuminuria, cardiac comorbidities, glucose lowering,
and anti-hypertensive medications showed the following HR
relative to the BMI 20 to 25 group in the 10,969 patients
hospitalized for HF: BMI 25 to 27.5 = 1.04, BMI 27.5 to
<30 = 1.22, 30 to <35 = 1.54, 35 to <40 = 2.16, ≥40 = 3.22
(P < 0.001).
Pathogenesis of Heart Failure in Patients with DM
HF may occur in the presence of reduced LVEF (HFrEF) or
preserved LVEF (HFpEF). The definition of Bnormal LVEF^
has varied over the years. In a 2015 joint guideline from the
American Society of Echocardiography and the European
Association of Cardiovascular Imaging, Bnormal LVEF^
was defined as being between 53 and 73 % [21]. Popular
norms set echocardiographic normative value as LVEF ≥
55 %; however, in many clinical trials and population-based
studies, values as low as ≥40 or 45 % have been considered
normal. In addition to LVEF, the patient demography, comor-
bid conditions, pathogenesis, outcomes, and responses to ther-
apies are somewhat different between the two types of HF
[22–25].
HFrEF
The primary abnormality in HFrEF is systolic dysfunction in
which there is impaired LV contraction and ejection of blood
[2, 26–28]. Most common causes are a loss of myocardial
mass, impaired myocardial contractility, volume, and/or pres-
sure overload. Hemodynamically, cardiac output is decreased
causing hypoperfusion of tissues, end LV systolic and diastol-
ic pressures and volumes are increased, and pulmonary con-
gestion occurs [26–28]. Major factors leading to impaired LV
systolic function are coronary ischemic disease and infarction,
uncontrolled hypertension, valvular incompetence, andmicro-
vascular disease. The decrease in cardiac output and hypoper-
fusion in HFrEF result in many adaptive responses.
Sympathetic nervous system activation causes increases in
norepinephrine and epinephrine, activation of the renin-
angiotensin-aldosterone system (RAAS), and increases in va-
sopressin [2, 26–28]. Atrial natriuretic peptide (ANP), ventric-
ular B-type natriuretic peptide (BNP), and C-type natriuretic
peptide secretions are increased in response to the elevation in
chamber pressure in HF [29]. Cytokines are released from the
vasculature and systemic endothelial activation with inflam-
mation results from HF [26, 27]. Chronically, the heart re-
sponds to HF with ventricular remodeling resulting in hyper-
trophy and an increased ventricular volume [2, 26–28]. Many
of the adaptive changes (e.g., hypertrophy, heightened sym-
pathetic tone) initially improve ventricular function, but even-
tually, they become maladaptive and serve to worsen the HF
(e.g., chamber enlargement, heightened sympathetic tone).
These adaptive changes include molecular remodeling as
well. There is reduced expression of SERCA2a, decreased
L-type calcium channels on the cardiac myocytes, reduced
phosphorylation of phospholamban leading to less SR reup-
take of calcium, and altered expression of the sodium-calcium
transporter [2, 3, 30, 31]. Treatment of HFrEF is largely fo-
cused on blocking or reversing the maladaptive responses and
facilitating the adaptive processes [31].
HFpEF
HF with preserved EF has been defined by the European
Society of Cardiology using the following criteria: (1) signs
or symptoms of HF, (2) normal or mildly abnormal systolic
LV function, (3) elevated levels of natriuretic peptides and at
least one of the two following criteria: relevant structural heart
disease (LVH and/or LAE) or diastolic dysfunction [1].
Normal or mildly abnormal systolic LV function was defined
as an LVEF ≥ 50 % and an LV end diastolic volume index
(LVEDVI) < 97 ml/m2. Diastolic LV dysfunction is consid-
ered as LV end diastolic pressure >16 mm Hg or mean pul-
monary capillary wedge pressure > 12mmHg [23]. The AHA
and ACC define HFpEF simply as HF in which the EF > 50%
[32].Many observers continue to equate HFpEFwith diastolic
dysfunction. The underlying abnormalities in most cases of
HFpEF are increased LV stiffness, impaired LV relaxation,
impaired contractile reserve, increased vascular stiffness and
inefficient ventriculo-arterial coupling, pulmonary hyperten-
sion, and abnormal cardiovascular response to exercise.
Emerging evidence points to microvascular dilatory dysfunc-
tion or rarefaction as a significant etiologic factor in the de-
velopment of diastolic dysfunction [22, 33–35]. The preva-
lence of HFpEF is greater in women, older age populations,
and in those with hypertension.
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Patients with DM are at high risk for both HFrEF and HFpEF
[11, 36, 37]. Approximately 40 % of diabetic subjects with HF
haveHFpEFwhich is similar to that in non-diabetic subjects with
HF. However, the overall incidence of HF in diabetic subjects is
2.5-fold greater, and clinical outcomes are significantly worse
than in the non-diabetic population [11, 38]. What factors can
explain these disparities? Ischemic heart disease and hyperten-
sion are comorbiditieswithDMand aremajor risk factors for HF.
However, numerous studies have shown that DM itself is an
independent risk factor for HF [17, 39••, 40, 41]. Diabetic car-
diomyopathy is a clinical condition inwhich ventricular dysfunc-
tion occurs in DM patients in the absence of coronary artery
disease (CAD) or hypertension [42–44]. It is often difficult to
isolate the contribution of cardiomyopathy from the other risk
factors such as CAD and hypertension because of their frequent
co-existence. In a nationwide study of hospital discharges of
44,837 patients with unexplained dilated cardiomyopathy and
450,254 matched controls, DMwas significantly more prevalent
in theHF group (adjustedOR= 1.58, 95%CI = 1.55–1.62) [45].
One potential reason for the occurrence of HF in patients with
DM independent of CAD or hypertension is the associated mi-
crovascular dysfunction characteristic of DM. Impaired reactive
hyperemia and other measures of microvascular dysfunction are
observed in DM and could explain the rate of HFpEF [34, 35].
An early feature of diabetic cardiomyopathy is diastolic
dysfunction.
Diabetes
DM leads to an increase in myocardial free fatty acid (FFA)
uptake and metabolism and a reduction in glucose metabo-
lism. The excessive myocardial FFA uptake and metabolism
are thought to lower LV diastolic and systolic function, in-
crease mitochondrial reactive oxygen stress (ROS), and cause
additional lipotoxic effects such as inflammation in myocar-
dial cells [39••, 40, 44]. Hyperglycemia elevates cardiomyo-
cyte glucose levels which generate advanced glycosylation
end-products (AGEs) and glucose toxicity. AGEs increase
ROS, can crosslink and damage collagen, and activate the
inflammatory cascade among its many effects. The net effect
of the multiple metabolic effects of DM on the myocardium is
to cause myocardial hypertrophy, myocardial fibrosis and
stiffness, myocardial microangiopathy, and impaired myocar-
dial contractility [25, 42].
If diabetic cardiomyopathy is due to microangiopathy and
the metabolic consequences of poorly regulated hyperglyce-
mia, it should be possible to prevent it by early and aggressive
management of the lipid and glucose abnormalities of DM [46].
Clinical Course of Heart Failure in Patients with Diabetes
The prognosis of patients with HF is poor. Community-based
studies indicate that 1-year mortality following diagnosis is 30
to 40 % and 5-year mortality is 40–60 %. Refractory HF or
sudden ventricular arrhythmia are the cause of death [47]. The
NYHA classification gives useful prognostic information for
an individual patient. Patients with NYHA class IV have a 30
to 70 % annual mortality while those with class II have an
annual mortality of 5 to 10 % [48].
Patients with DM and HF have a poorer outcome than non-
diabetic patients. In the REACH Registry of 45,227 HF pa-
tients, 43.6 % of whom had DM, the 4-year HR of cardiovas-
cular death, non-fatal MI or non-fatal stroke in the diabetic
population (16.5 %) compared to the nondiabetic (13.1 %)
was 1.27, P < 0.001. CV death occurred in 8.9 versus 6.0 %
(P < 0.001) and overall death 14.3 versus 9.9 % (P < 0.001)
(DM versus non-diabetic individuals). DM patients had a
33 % greater rate of hospitalizations for HF, 9.4 vs 5.9 %
(P < 0.001). In the patients with HF at baseline, the HR for
cardiovascular death in the diabetic population was 2.45, and
for hospitalization for HF, it was 4.72 (P < 0.001) [5••].
An analysis of the impact of DM on outcomes in patients
with HFrEF and HFpEF performed in 7599 patients with
symptomatic HF followed for a median of 37.7 months in
the Candesartan in Heart failure-Assessment of Reduction in
Mortality and morbidity (CHARM) program showed that DM
was an independent predictor of CV mortality and morbidity
regardless of EF. The prevalence of DM was 28.3 % in those
with preserved EF and 28.5 % in those with reduced EF. For
the entire population of 2163 participants with DM, the rates
of death and hospitalizations fromCV disease (94.4 and 306.5
per 1000 patient years of follow-up, respectively) were greater
than those for the 5436 non-diabetic population (57.5 and
207.4 per 1000 patient years of follow-up, respectively,
P < 0.001). The patients with DM and preserved EF had worse
outcomes (CV death and HF hospitalization) relative to those
without DM who had HFpEF (HR = 2.0, P < 0.0001). In par-
ticipants with DM and low EF, DM was an independent pre-
dictor of CV death or HF hospitalization with an HR of 1.60
(P < 0.0001) compared to non-diabetic individuals [11]. In the
Digitalis Investigation Group (DIG) ancillary study which
compared participants with DM and HFpEF to participants
without DM but with HFpEF, DM was associated with a
68 % increased risk of HF hospitalization or HF death during
a mean follow-up of 37 months [37].
Several studies have assessed the impact of fasting plasma
glucose on outcomes of patients with HF. A retrospective
analysis of the effect of fasting plasma glucose on outcomes
in 6607 patients with HF followed in a Jerusalem Health
Maintenance Organization indicated that impaired fasting
plasma glucose (IFG) and elevated plasma glucose (DM) pre-
dict reduced survival (HR = 1.42 for DM; 1.55 for IFG,
P < 0.01 for both) and increased cardiac-related hospitaliza-
tions (HR = 1.31, P < 0.001 for DM; 1.17, P < 0.05 for IFG)
when compared to HF patients with fasting glucoses 92 to
99 mg/dl. Forty-eight percent of the patients had DM and
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11 % had IFG. The mean follow-up was 487 days, and the
mean age at inclusion was 75 ± 13 years [49].
Undiagnosed DM is a frequent occurrence in patients hospi-
talized for HF. In a series of 400 patients admitted consecutively
for acute HF, 47 % did not have DM, 37 % had known clinical
DM, and 16 % were previously undiagnosed with DM but had
two fasting plasma glucoses ≥7.0 mmol/l before or after the
acute episode. Despite having comparable CV risk factors, the
patients with undiagnosed DM had a 7-year total and CV mor-
tality that was significantly higher than those without DM
(HR= 1.69, 95 % CI = 1.17–2.46 and 2.45, 95 % CI = 1.58–
3.81, respectively) and similar to those with known DM who
had a much higher CV risk profile [50]. The Worcester Heart
Failure Study (WHES) was a population-based surveillance
study of adult residents of the Worcester, MA metropolitan area
admitted to all 11 central Massachusetts medical centers for
acute decompensated HF during the years 1995, 2000, 2002,
and 2004. The total population surveyed consisted of 5428 in-
dividuals without DM (glucose 124.8 ± 28 mg/dl), 3807 with
diagnosed DM (glucose 191 ± 96 mg/dl), and 513 with admis-
sion hyperglycemia (glucose 260.5 ± 65 mg/dl). The highest in-
hospital death rate occurred in those with admission hypergly-
cemia (9.9 %) compared to 6.5 % in patients with known DM
and 7.5 % in individuals without DM [51•]. This is consistent
with the observations that patients admitted with an acute illness
who have severe hyperglycemia have previously unrecognized
and uncontrolled DM or have a severe illness that causes mark-
edly excessive neuroregulatory and cytokine responses [52].
The Meta-Analysis Global Group in Chronic Heart Failure
(MAGGIC) reported an analysis of individual data on 39,372
patients with bothHFrEF andHFpEF from 30 cohort studies. A
total of 40.2 % of the patients during a median follow-up of
2.5 years died. They constructed a model from the data to
predict mortality from HF. The model includes 13 independent
predictors of mortality. The order of predictive strength is age,
lower EF, NHYA class, serum creatinine, DM, absence of pre-
scribed beta-blocker, lower systolic blood pressure, lower body
mass, time since diagnosis, current smoker, chronic obstructive
pulmonary disease, male gender, and absence of a prescribed
RAAS inhibitor [53]. In HFpEF, age was more predictive, and
systolic blood pressure was less predictive of mortality than in
HFrEF. The Web site address for the MAGGIC calculator for
all-cause mortality for 1 and 3 years is http://www.
heartfailurerisk.org. An alternative predictive model for
survival in HF is the Seattle Heart Failure Model [54].
Treatment of Heart Failure in Patients with Diabetes
The treatment of HF in the patient with DM is similar to the
individual without DM with the added complication of the
impact that glycemic control and the anti-hyperglycemic agents
used have on clinical HF outcomes. In both the diabetic and
non-diabetic populations, treatment for HF with reduced LVEF
(<40 %) provides a significant benefit in reducing total mortal-
ity, CV mortality, and hospitalization for progressive HF. In
contrast, these same therapies do not result in improved survival
in patients with HF with preserved LVEF (>45 or 50 %).
Patients with HFrEF–LVEF ≤ 40 %
Blockade of the RAAS
In patients with HFrEF, therapy is directed toward reversing the
maladaptive effects that occur because of the activation of the
sympathetic nervous system and the RAAS. Angiotensin
converting enzyme inhibitors (ACEI), which block the conver-
sion of angiotensin I to angiotensin II, reduce total mortality
23% and the combined end point of mortality or hospitalization
for HF 35 % [55]. The effects are similar among the different
ACEI [56–59]. Patients with the lowest EF appear to have the
greatest benefit with the greatest effects occurring in the first
few months of treatment. The reduction in mortality is due to
fewer deaths from progressive HF. ACEI have little if any effect
on sudden, arrhythmic death. ACEI block the production or
metabolism of many peptides other than angiotensin II. Their
use is associated with significant side effects such as cough,
angioedema, symptomatic hypotension, and renal dysfunction.
Because angiotensin II receptor blockers (ARBs) effective-
ly reduce angiotensin II effects without the side effects of
ACEIs, their value in treating HF has been evaluated in many
clinical trials. The initial trials examined the effects of adding
an ARB to patients with HFrEF on standard care including
ACEIs and to HFrEF patients unable to take ACEIs because
of intolerance to their side effects. Valsartan added to HFrEF
patients NYHA class II–IV receiving standard care (93.5 % on
ACEIs, 35 % on β-adrenergic blockers, 5 % on
spironolactone) did not reduce overall mortality but did de-
crease the combined endpoint of mortality and hospitalization
for progressive HR by 13.2 % [60]. This was primarily due to
the lower number of patients hospitalized for HF (18.2 % in
the placebo-treated group versus 13.8 % in the valsartan-
treated group, P < 0.001). A post hoc analysis of the data
suggested that adding valsartan to patients taking both an
ACEI and a β-adrenergic blocker increased mortality (P =
0.009) and showed a tendency toward a poorer combined
outcome as compared to placebo treatment. The post hoc anal-
ysis also suggested that the effect of valsartan on the combined
endpoint was not significant in the 25 % of the patients with
HF and DM. The response to valsartan addition appeared to be
somewhat better in the 366 patients not taking an ACEI [61].
Compared to the placebo, both all-cause mortality and com-
bined all-cause mortality and CV morbidity in the valsartan
group were significantly less (17.3 versus 27.1 % and 24.9
versus 42.5 %, respectively). It appeared that an ARB could
replace an ACEI with at least equal benefits.
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A comparable series of studies with candesartan in patients
with HFrEF and NYHA class II–IV yielded slightly different
results. Candesartan added to patients taking ACEIs 100 %,
β-adrenergic blockers 55 %, and spironolactone 17 %, de-
creased CV death or hospital admission for HF over a median
duration of treatment of 41 months by 15 % (38 % events in
candesartan group versus 42 % in placebo group, P = 0.01)
[62]. CV deaths were reduced by 16 % and hospitalization for
HF by 17 %. In this study, patients on ACEIs and β-
adrenergic blockers had the same benefits from candesartan
as all other patients. Adding candesartan to patients with
HFrEF not taking ACEIs because of intolerance resulted in a
23 % reduction on CV death and hospitalization for HF, a
15 % reduction in CV death, and a 32 % reduction in hospi-
talization for HF [6]. Adding an ARB to an ACEI increases
the incidence of increasing renal dysfunction and
hyperkalemia [6, 61]. The combination ACEI and ARB
blocker does not appear to provide significant clinical benefit
but is associated with more significant side effects.
Blocking the RAAS improves clinical outcomes in patients
with HFrEF. The magnitude of the benefit depends on suffi-
ciently blocking the RAAS and is therefore dependent on the
dose of the inhibitor or blocker used. There is no clear data as
to the effectiveness of RAAS inhibition on HF outcomes in
patients with DM as compared to those without DM.
Renin Inhibition
A large clinical trial examined the effect of a renin inhibitor
(aliskiren) compared to enalapril or combined with enalapril
on the primary outcome of death from CV causes or hospital-
ization for HF. Participants were randomized to enalapril 5 or
10 mg twice a day (n = 2336), aliskiren 300 mg once daily
(n = 2340), or enalapril + aliskiren (n = 2340). After a median
follow-up of 36.6 months, the primary outcome occurred in
32.0 % of the combined therapy group, 34.6 % in the enalapril
group, and 33.8 % in the aliskiren group. Aliskiren alone or
combined with enalapril provided no addition benefit on the
clinical outcomes. The combination of aliskiren and enalapril
increased the risk of hypotensive symptoms, an elevated se-
rum creatinine, and hyperkalemia [63].
B-adrenergic Blockade
B-adrenergic blocking agents improve functional status and
reduce morbidity and mortality in patients with HFrEF. In
order tominimize adverse effects such as impaired recognition
of clinical hypoglycemia, deterioration of glycemic control,
elevation of lipids, bronchospasm, and inhibition of vasodila-
tor effects of β2-adrenergic stimulation, cardio-specific β1-
receptor antagonist are recommended. Bisoprolol adminis-
tered for a mean of 1.3 years to patients with NYHA class
III and IV HF with an EF ≤ 35 % receiving standard therapy
with diuretics and ACEIs reduced all-cause mortality by 34 %
and sudden deaths by 44 % compared to placebo treatment
(P < 0.0001) [64]. Metoprolol CR/XL in the Metoprolol CR/
XL Randomized Intervention Trial in-Congestive Heart
Failure (MERIT-HF) trial involving 3991 participants with
NYHA class II-IVand EF ≤ 40% on standard therapy reduced
all-cause mortality at 1 year of follow-up by 34.5 % compared
to placebo (P < 0.001). Sudden death was reduced by 41 %
and death from worsening HF by 49 %. The metoprolol dose
was started at 12.5 or 25mg daily and up-titrated over 8 weeks
to 200 mg daily [65]. Similar results were obtained by carve-
dilol treatment of patients with severe chronic HF (symptoms
at rest or with minimal exertion and an EF < 25 %). In the
carvedilol prospective randomized cumulative survival
(COPERNICUS) study, after an average treatment of
10.8 months, there were 190 deaths in the placebo-treated
group and 130 in the carvedilol group for a risk reduction of
35 %, P < 0.001. Carvedilol reduced the combination of CV
death or hospitalization for HF by 31 %, P < 0.001 [66, 67].
The carvedilol-treated participants spent 27 % fewer days in
the hospital and experienced a serious adverse event like sud-
den death, cardiogenic shock, or ventricular tachycardia less
than placebo-treated participants (P < 0.002). β-adrenergic
blockade has dramatic effects in reducing mortality and sud-
den death in particular. Metoprolol succinate, carvedilol, and
bisoprolol are the currently marketed β-adrenergic blockers in
the USA shown to exert a mortality benefit in HFrEF.
Mineralocorticoid Receptor Antagonists
In clinical trials, the mineralocorticoid receptor antagonists,
spironolactone and eplerenone, have been shown to increase
survival among patients with severe systolic HF. In the
Randomized Aldactone Evaluation Study, 25 mg of
spironolactone and placebo were administered to 1663 partic-
ipants who had severe HF and a LVEF ≤ 35 % and were being
treated with an ACEI, a loop diuretic, and in most cases di-
goxin. The primary endpoint was death from all causes. The
study was terminated early after a mean follow-up of
24 months. Forty-six percent of participants died in the place-
bo arm and 35 % in the spironolactone arm, for a risk reduc-
tion (RR) of 30 %, P < 0.001. The risk reduction in the
spironolactone-treated group was attributed to both a reduc-
tion in sudden death from cardiac disease and a decrease in
death due to progressive HF [68]. Participants who received
spironolactone had a 35 % lower frequency of hospital admis-
sion for worsening HF (P < 0.001) and an improvement in
NYHA functional class (P < 0.001). Similar results were ob-
served in a NYHA class II population treated with eplerenone
(up to 50 mg/day) for a median duration of 21 months. A
composite end point of death from a CV cause or hospitaliza-
tion for HF occurred in 25.9 % of the placebo group and
18.3 % in the eplerenone group for an RR of 37 %
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(P < 0.001) [69]. All-cause mortality and CV mortality were
decreased 34 % (P < 0.01). A serum potassium level exceed-
ing 5.5 mmol/l occurred in 11.8 % of the eplerenone-treated
participants and 7.2 % in the placebo-treated participants. Use
of a mineralocorticoid receptor antagonist is accepted as stan-
dard of care for symptomatic patients with HFrEF (EF <
35 %) who are also taking beta-adrenergic blockers and either
ACEI or ARB. Monitoring serum potassium levels should be
done routinely.
Angiotensin-Neprilysin Inhibition
One of the physiologic adjustments to HF is an increase in the
secretion of atrial natriuretic hormone and BNP. These hor-
mones are released in response to myocardial stretching in the
atria and the ventricles and induce diuresis, natriuresis, and
vasodilatation as well as inhibiting the sympathetic nervous
system [29, 70]. Attempts to treat HF with recombinant hu-
man BNP were unsuccessful with several clinical trials show-
ing no significant beneficial effects and some possible toxic
effects [29, 70]. An approach which has been successful is the
development of agents to block the enzyme neprilysin that
metabolize NPs and increase endogenous NP levels [71].
One such agent is AH 377 (sacubitril), a prodrug that is rap-
idly metabolized into a biologically active neprilysin inhibitor.
This was coupled to valsartan, and the angiotensin-neprilysin
(sacubitril/valsartan) inhibitor has been shown in the
PARADIGM-HF trial to be more effective in treating HF than
enalapril [7]. The combined inhibitor (LCZ696) at 200 mg
twice a day was compared to 10 mg enalapril twice a day in
a double-blind, randomized trial involving 8442 participants
with NYHA HF class II, III, or IV and a LVEF ≤ 40 %. The
trial was stopped early after a median follow-up on 27months.
The primary outcome, a composite of death from CV causes
or hospitalization for HF, occurred in 21.8 % of the LCZ696-
treated participants and 26.5 % of the enalapril-treated partic-
ipants (RR = 20%, P < 0.001). The RR for all-cause mortality
was 16 %, for CV death 20 %, and for hospitalizations for HF
was 21 %.
A recent analysis of the PARADIGM-HF data examined
the risk related to pre-diabetes and DM [12]. Patients with a
baseline history of DM (n = 2907, 35 %) had a higher risk of
the primary composite outcome of HF hospitalization or CV
mortality compared to those without a history of DM
(n = 5492), (adjusted HR = 1.38, P < 0.001). Baseline
HbA1c measurements showed that an additional 1106
(13 %) participants had undiagnosed DM (HbA1c ≥ 6.5 %)
and 2103 (25 %) had pre-diabetes (HbA1c 6.0–6.4 %). The
HRs for the composite primary outcome in participants with
previously known DM, those with previously unknown DM,
and those with pre-diabetes compared to participants without
DM (HbA1c < 6.0 %) were 1.64, 1.39, and 1.27, respectively,
P < 0.001 for all three groups. In this large clinical trial which
randomly recruited participants with reduced LVEF, 49 % of
the participants had DM and 25 % had pre-diabetes. The pri-
mary clinical outcomes over 27 months were increasingly
worse going from normoglycemia to pre-diabetes to newly
diagnosed DM to known DM. Some benefit of LCZ696
(sacubitril/valsartan) treatment compared to enalapril treat-
ment on clinical outcomes was observed irrespective of gly-
cemic status. The HRs for the primary composite outcome
comparing sacubitril/valsartan to enalapril treatment going
from normoglycemic to pre-diabetes to newly diagnosed
DM to known DM were 0.68 to 0.76 to 0.97 to 0.87. The
occurrence of DM in the patient with HF results in worse
clinical outcomes and poorer responses to current medical
therapy.
If Current Blockade
Ivabradine blocks the If current responsible for automaticity in
the sinoatrial node of the heart. Its primary action is to slow
heart rate without affecting ventricular myocardium. In pa-
tients with persistently elevated heart rates despite the use of
β-adrenergic blockers, Ivabradine can slow the heart rate, im-
prove left ventricular filling, and reduce mortality. The SHIFT
trial (Ivabradine in addition to beta blockade therapy for par-
ticipants with mild to moderate HF and heart rates above
70 bpm) showed that the 2-year composite outcome of cardio-
vascular death or hospital admission was less in the group
treated with Ivabradine than in those randomized to placebo
(HR = 0.74, P < 0.001) [72]. In a post hoc analysis of the
participants in the SHIFT trial, the prevalence of DM in the
population was 30 % of whom 32 % were being treated with
insulin. The participants with DM had an increase in the pri-
mary outcome of CV death or hospitalization for worsening
HF compared to the non-diabetic population (HR = 1.18, P =
0.001) [73]. The beneficial effects of Ivabradine occurred in
the diabetic population (HR = 0.80) as well as the non-diabetic
population (HR = 0.84).
Other Medical Therapies Not Shown to Have a Mortality
Benefit
In patients with HFrEF NYHA classes II–IV, about 85 % of
patients ordinarily require treatment with diuretics, and loop
diuretics are preferred. Approximately 50 % of patients with
HFrEF are administered a digitalis preparation. Clinical trials
have shown that digoxin has no effect on overall mortality but
does cause a reduction in the rate of hospitalization for overall
and worsening HF in patients with HFrEF [74]. In an ancillary
study, digoxin had no effect on either mortality or morbidity in
patients with HFpEF [75]. Both diuretics and digitalis are used
primarily for symptomatic improvement; however, the thera-
peutic window for digitalis is rather narrow, limiting its clin-
ical utility.
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Non-surgical Device Treatments
When medical therapy fails after an appropriate trial, medical
device therapy can be considered. Implantable cardioverter-
defibrillator (ICD) is useful for both primary and secondary
prevention of sudden death from ventricular arrhythmia.
Cardiac resynchronization therapy (CRT) can be considered
in symptomatic patients with HF in sinus rhythm with a
QRS ≥ 150 msec with or without left bundle branch block
morphology and an EF ≤ 35 % to improve symptoms and
reduce morbidity and mortality. Device therapy requires eval-
uation and chronic care by cardiologists with specific exper-
tise in the use of these devices.
A device approved in European countries and still in clin-
ical trials in the USA is cardiac contractility modulation
(CCM) which involves non-excitable electrical stimulation
of the ventricles during the absolute refractory period to en-
hance contractile performance.
There is no information as to the benefit of these devices in
the patient with HF with DM as contrasted to subjects without
DM. A detailed discussion of device therapy for HF can be
obtained in the 2016 ESC Guidelines for the diagnosis and
treatment of acute and chronic HF [1].
Patients with HFpEF–LVEF > 40 %
Though much knowledge and understanding about the path-
ophysiology of HFpEF has been obtained in the last decade,
there is, as yet, no treatment identified that provides a proven
mortality benefit. Several clinical trials suggest a possible ben-
efit in morbidity and a large trial with ARB/neprilysin inhibi-
tion is ongoing.
Angiotensin Receptor Blockade
The CHARM Preserved Trial recruited 3023 participants with
NYHA classes II–IVand LVEF > 40%.Median follow-up was
36.6 months, and the primary outcome was CV death or hos-
pital admission for HF. Patients were randomized to
candesartan 32 mg once daily or placebo. Of the cohort, 22 %
of the candesartan and 24 % on the placebo group experienced
the primary outcome (HR 0.89, P = 0.118). There was no dif-
ference in CV death (170 participants in each group), but fewer
participants on candesartan had a hospital admission for HF
(230 versus 279, P = 0.017) [76]. A trial involving 4128 partic-
ipants (≥60 years) with NYHA class II–IV, LVEF ≥ 45 % ran-
domized subjects to irbesartan versus placebo. After a mean
follow-up of 49 months, there was no significant difference
between the two groups in primary outcome of death from
any cause or hospital admission for a CV cause [77].
The paramount trial was a phase II trial in participants with
NYHA class II–IV, LVEF ≥45 %, and NT-proBNP > 400 pg/
ml to evaluate the effect of LCZ696 200mg twice a day versus
valsartan 160 mg twice daily on NT-proBNP levels at
12weeks. LCZ696 lowered theNT-proBNP levels by 4weeks
and maintained those levels through 36 weeks [78]. Valsartan
caused a slow progressive decrease in NT-proBNP during the
entire 36 weeks. The improvement by LCZ696 treatment over
valsartan was significantly different at 4 and 12 weeks, but not
at 36 weeks. LCZ696 caused a greater BP reduction at 12 and
36 weeks. The preliminary data from this pilot study was used
to help design the large ongoing PARAGON-HF in HFpEF
study which will study the effect of LCZ676 on clinical out-
comes in participants with HFpEF.
Treatment of Hyperglycemia in Patients
with Diabetes and Heart Failure
Patients with T2DM have a marked increase in the prevalence
of HF and have a poorer prognosis when they develop HF
than non-diabetic individuals. A major consideration is the
extent to which hyperglycemia itself contributes to these dis-
parities. Hyperglycemia may impact HF in several ways: (1)
chronic hyperglycemia may contribute to the development of
HF, (2) hyperglycemia may worsen the outcome of acute HF,
(3) chronic hyperglycemic management in the patient with
chronic HF may influence clinical outcomes, (4) specific
anti-hyperglycemic agents may have direct effects on the de-
velopment and/or clinical outcomes of HF.
As noted in the section on epidemiology, observational
studies have shown a striking relationship between HbA1c
and the development of HF in patients with T2DM and no
HF at baseline. During a mean follow-up of 2.2 years, each
1 % increase in HbA1c was associated with an 8 % increase in
HF and for a mean follow-up of 7 years, HF development
increased progressively from <5 % with an HbA1c of 7.0 to
72 % with an HbA1c greater than 10 % [18].
The level of chronic glycemic control and the stage of HF
determine the clinical outcomes of CV death and hospitaliza-
tion for HF in patients with DM. The large clinical interven-
tion trials in participants with T2DM to determine the effect of
intensive (HbA1c 6.5 to 6.8 %) versus ordinary glycemic con-
trol (HbA1c 7.5 to 8.0 %) on CV events failed to show any
effect on HF outcomes (HR = 1.00, 95 % CI = 0.86–1.16)
[79]. While these trials included 27,049 participants, the base-
line incidence of HF was very low (approximately 5 %), and
only 905 participants were hospitalized for HF annually. The
overall difference in mean HbA1c between the groups in all of
those intervention trials was 0.9 %.
In contrast, observational studies in patients with HF and
DM show a strong relationship between glycemic control and
clinical outcomes. In a population-based study of 16,524 pa-
tients seen in emergency departments in Ontario, Canada with
acute HF syndromes, the presenting blood glucose level pre-
dicted clinical outcomes [80]. A presenting blood glucose
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>11.1 mmol/l in patients with DM (n = 7249) was associated
with an increased risk of all-cause death (HR = 1.48, P = 0.01)
or DM-related hospitalizations (HR = 1.39, P < 0.001). A pre-
senting blood glucose >9.4 mmol/L was associated with an
increase in risk of hospitalization for HF (HR = 1.15, P =
0.002) or any CV cause (HR = 1.09, P = 0.009) in the entire
patient population [80]. TheWorcesterWHES study observed
the effects of elevated serum glucose levels on survival after
acute HF in 5428 non-diabetic patients, 3807 patients with
diagnosed DM, and 513 patients with admission hyperglyce-
mia. In-hospital death rate was highest in those with admission
hyperglycemia (9.9 %) as compared to individuals without
DM (7.5 %) and those with known DM (6.5 %). In contrast,
the patients with known DM had the highest death rates
3 months (HR = 1.14 compared to those without DM, 95 %
CI = 1.09–1.20) and 1 and 2 years (HR = 1.18, 95 % CI =
1.11–1.24) after discharge [51•].
The ASTRONAUT trial (aliskren) [81] and the EVEREST
trial (tolvaptan) [82] were clinical trials in participants hospi-
talized for symptomatic HF. In both studies, the participants
were assessed for post-discharge outcomes, and differences
were determined in participants with known DM as compared
to participants without DM. The extent of glycemic control
was not monitored by glucose levels or HbA1c in either study.
ASTRONAUT trial showed no difference in inpatient out-
comes between participants with and without DM. However,
12 months after discharge, participants with DM had higher
CV mortality or hospitalization for HF (non-diabetic HR =
0.80; diabetic HR = 1.15, P < 0.03). A mean of 9.9 months
after discharge, participants with DM in the EVEREST trial
had a 17 % increase in CV mortality or hospital admission for
HF. Patients with DM in the EVEREST trial were treated by
diet (20 %), oral agents (36 %), or insulin (48 %). The insulin-
treated group had an increase in the outcome of CV mortality
or HF hospitalization (HR = 1.25, 95 % CI = 1.00–1.57) com-
pared to the other treatments. The increase in outcome events
in the short-term post-discharge period of these two studies
suggests an influence of glycemic control on outcomes in
participants with DM and HFrEF.
Several retrospective studies have examined the effect of
the intensity of glycemic control on mortality in patients with
DM and chronic HF. Table 2 summarizes the results from
three such studies, and all indicate that there is a U-shaped
relationship between mortality and HbA1c levels [83–85].
The most comprehensive study examined the mortality during
a 2-year follow-up period from the database records of 5815
patients with DM and HF managed in ambulatory clinics in
VAMedical Centers [83]. Ninety-four percent of patients were
male with a mean age of 69.2 years; 45 % had reduced LVEF
and 55 % had preserved LVEF. The other two studies were
each from a single center, included only patients with reduced
LVEF, and reported data from a 2-year follow-up [84, 85]. The
patients in the Tomova et al. study had more severe HF with
75 % NYHA class III and IV [84]. The data from the three
studies suggest that the lowest mortality occurs when glyce-
mic control maintains the HbA1c between 7.5 and 8.0 %
(Table 2).
An additional issue in treating the patient with DM and HF
is the choice of anti-hyperglycemic agents used. There are no
adequate clinical trials of metformin, sulfonylurea, or ordinary
insulin dose on HF pathogenesis or treatment. The only data
available are from observational studies. A retrospective anal-
ysis of 6185 patients with HF and DM treated in ambulatory
clinics in Veterans Affairs medical centers and followed for
2 years showed a propensity score adjusted mortality in
metformin-treated patients of 16.1 versus 19.8 % in patients
not treated with metformin (HR = 0.76, P < 0.01). HF hospi-
talization was no different between metformin treatment and
no metformin treatment [86]. Based on the US and Canadian
cardiac failure data, treatment with metformin is not absolute-
ly contraindicated in patients who have isolated HF. The risk
of lactic acidosis due to metformin is negligible in these
Table 2 Glycemic control and mortality in patients with heart failure and diabetes
Aguilar et al. [83] Tomova GS et al. [84] Eshaghian S et al. [85]
N = 5815 Mortality at 2 years N = 358 Mortality or urgent
heart transplantation
at 2 years
N = 123 Mortality at 2 years
Quintile 1
HbA1c ≤ 6.4 %
25 % Quartile 1
HbA1c ≤6.4 %





HbA1c 6.4 to ≤7.1 %
23 % Quartile 2
HbA1c 6.5 to 7.2 %
58 % Quartile 2




HbA1c 7.1 to ≤7.8 %
17.7 % Quartile 3
HbA1c 7.3 to 8.5 %
39 % Quartile 3




HbA1c 7.8 to ≤9.0 %
22.5 % Quartile 4
HbA1c ≥8.6 %





HbA1c > 9.0 %
23.2 %
Curr Diab Rep (2016) 16: 116 Page 9 of 14 116
patients and is unrelated to the plasma concentration of met-
formin. Metformin-associated lactic acidosis may occur when
kidney function is decreased in patients with decompensated
HF.Metformin provides a greater degree of CV protection and
should not be withheld in patients with DM with stable HF
who do not have other risk factors for acute decompensated
HF or lactic acidosis [87].
In a single center observational study of 554 consecutive
patients with advanced systolic HF, patients were stratified
into 3 groups: 43 patients with DM were treated with insulin
and 89 were non-insulin-treated. The 1-year survival was
89.7 % in the 422 patients without DM, 85.8 % in the non-
insulin-treated patients with DM, and 62.1 % for the insulin-
treated patients with DM, P < 0.00001. After Coxmultivariate
analysis, insulin-treated DM was found to be an independent
predictor of mortality (HR = 4.30, 95 % CI = 1.69–10.94)
whereas non-insulin-treated DM was not (HR = 0.95, 95 %
CI = 0.31–2.93) [88]. A large CV outcome trial (ORIGIN)
comparing low-dose basal insulin glargine to standard DM
care which was carried out in 12,537 participants with pre-
diabetes and newly diagnosed T2DM over a median duration
of 6.2 years found neither a beneficial nor detrimental effect of
insulin glargine on the development of HF [89]. The study
was not designed to specifically study HF, and only 310 of
6264 participants on insulin glargine and 343 of 6273 partic-
ipants on standard care were hospitalized for HF. The mean
HbA1c for the insulin glargine and standard treatment groups
for the study were 6.2 and 6.5 %, respectively. Appropriate
interventional trials will be necessary to assess the effects of
insulin treatment on development and outcomes of HF.
The first clear evidence that anti-hyperglycemic drugs
could cause and worsen HF in DM patients was shown with
the thiazolidinediones (PPARγ agonists). Pioglitazone and
rosiglitazone increase sodium retention by the kidney and
cause increased fluid retention which leads to edema and an
increase in both the incidence of HF and an increased rate of
hospital admissions for HF [90, 91]. These drugs should not
be used in patients with T2DM and HF. As noted previously,
despite insufficient data about the effect of insulin treatment
on outcomes in patients with T2DM and HF, the potential
dangers of hypoglycemia are sufficiently serious in this pop-
ulation to limit insulin use.
The effect of DPP-4 inhibitors in patients with T2DM and
HF is complicated. The CV outcome trials show that
saxagliptin increases hospitalizations for HF in patients with
T2DM [92]. The alogliptin trial suggests, but is not definitive,
that it too may increase HF hospitalizations [93], while the
sitagliptin trial shows no effect on HF morbidity in patients
with T2DM [94]. The unresolved question is whether the in-
crease in HF is a class effect and the differences in results due
to differences in clinical design of the trials or whether the
effect has little to do with DPP-4 inhibition. At the present
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in patients with T2DM and HF, sitagliptin would be the one to
use.
The LEADER trial with the GLP-1 receptor agonist
liraglutide showed no specific effect on HF outcome but did
show a decrease in CV mortality in participants with T2DM
[95]. Thus, it and perhaps other GLP-1 receptor agonists may
be useful in treating the patient with T2DM and HF.
The EMPA-REG CV outcome trial unexpectedly showed
that the SGLT-2 inhibitor, empagliflozin, has a unique benefit
in decreasing both HF hospitalization and death in participants
with T2DM at high risk for CVevents [96•]. The mechanism
for this effect is unknown but may be related to its effects in
causing weight loss, reducing plasma volume, lowering sys-
tolic blood pressure, and/or creating a more ketogenic metab-
olism. A specific outcome trial of empagliflozin in patients
with T2DM and HF is needed to verify that the benefits suf-
ficiently outweigh potential side effects before this can be
recommended as a preferred treatment. CV safety trials with
other SGLT-2 inhibitors such as canagliflozin and
dapagliflozin, which will be completed in the next year or
two, will show whether the effects on HF outcomes are class
effects.
The US FDA has mandated that all new DM drugs must be
evaluated for CV safety. This has spawned a large number of
completed and ongoing clinical CV trials (Table 3). The trials
are primarily designed with the primary endpoint being devel-
opment of first major CV events defined as CV death, non-
fatal myocardial infarction, and non-fatal stroke. HF has not
been amajor end point, and the studies are not powered for HF
outcomes. Nonetheless, data have emerged from some of
these trials which have generated significant interest in the
indication or contraindication of some of these drugs for the
treatment of T2DM patients with HF (Table 3).
Conclusions
Evolving data on HF and DM indicate that DM is present in as
many as 50 % of patients presenting with HF. Those patients
with DM and HF have a significantly worse outcome than
patients with HF and no DM. The person with DM and HF
responds less well to medical HF treatments than patients with
normal glycemia. The effects of DM on HF is related to the
degree of metabolic derangement and are seen even in the pre-
diabetic state. Treatment of the patient with DM and HF re-
quires the simultaneous treatment of both the HF and the
hyperglycemia. The impact of anti-hyperglycemic agents on
the development of HF and its clinical outcomes may open
new approaches to treatment. The worldwide incidence of
T2DM is increasing in epidemic proportions with the number
of patients with DM expected to exceed 640 million by 2040.
The majority of patients are developing T2DM in middle age
(30 to 60 years) and surviving well into their 70s and 90s. It
can be anticipated that the increase in DM and the aging of the
population will lead to a marked increase in the number of
patients with DM and HF. The increasing number and poor
prognosis of DM patients with HF requires the development
of new strategies to prevent and to treat this increasing impor-
tant complication of DM.
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